While there likely is not a future for single-agent mosunetuzumab, the combination of mosunetuzumab and polatuzumab vedotin (M-Pola) has been evaluated in a phase Ib/II study in patients with MCL and progressive disease post BTK inhibitor [34]. The gene discussed is BTK; the disease is mantle cell lymphoma.